Denikitug Biosimilar - Research Grade

Human

CCR8

>1mg/ml

IgG1 - kappa

CHO Cells

Azirkitug Biosimilar - Research Grade (ICH5368), Cafelkibart Biosimilar - Research Grade (ICH5420), Lanerkitug Biosimilar - Research Grade (ICH5625)

https://www.imgt.org/mAb-DB/

ICH3002

P51685

1237

Blue ice

This product is a research-grade biosimilar of denikitug, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. Denikitug (also known by its development designation GS-1811) is a humanized IgG1 monoclonal antibody directed against human C-C chemokine receptor type 8 (CCR8), and this reagent is built around that same target and human IgG1, kappa framework rather than around a defined hybridoma clone. It is intended to recapitulate the binding characteristics of the originator so investigators can use it as a reference or comparator molecule in binding, blocking, and effector-function assays. Because it is a non-therapeutic research analog, it is not formulated or released for clinical use, and it should not be equated with the clinical drug product. The originator program has been advanced as a tumor-infiltrating regulatory T cell (Treg) depleting agent in oncology, and this biosimilar allows laboratories to interrogate CCR8 biology, antibody-target engagement, and Fc-dependent activities in controlled experimental systems. Low-endotoxin research-grade material and bulk milligram-to-gram quantities support reproducible in-vitro and standardization work. CCR8 (UniProt P51685) is a seven-transmembrane G protein-coupled chemokine receptor whose dominant functional ligand is CCL1, with additional reported binding by CCL8, CCL16, and CCL18. In humans, CCR8 is expressed at high levels on effector tumor-infiltrating regulatory T cells (TI-Tregs) while showing comparatively low expression on peripheral Tregs and conventional T cells, which underlies its appeal as a selective immuno-oncology target. Signaling through the CCL1-CCR8 axis promotes Treg migration, retention, and immunosuppressive function within the tumor microenvironment. Because CCR8+ TI-Tregs help suppress cytotoxic CD8+ and conventional CD4+ T-cell responses, antibodies that engage CCR8 are being explored to deplete these cells (via ADCC/ADCP) and/or block CCL1 signaling, with the goal of restoring antitumor immunity. Its restricted expression pattern is central to the therapeutic rationale.

CC-CKR-8, CCR-8, CDw198, CKRL1, CMKBR8, CMKBRL2, CY6, GPRCY6, TER1, C-C motif chemokine receptor 8

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Denikitug (anti-CCR8) Biosimilar

Q: Is the Denikitug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Denikitug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Denikitug biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Denikitug that binds CCR8; for research use only.